

CONTENTS

List of Abbreviation	(i)
List of Figures	(ii) – (v)
List of Tables	(vi)
Summary	(vii) – (xiv)
1.0 INTRODUCTION	1-74
2.0 MATERIALS	75
3.0 METHODS	76-94
3.1 Purification of buffalo liver cystatin	76
3.2 Colorimetric analysis	77
3.3 Slab gel electrophoresis	79
3.4 Staining of the gel	80
3.5 Molecular weight determination	80
3.6 Immunological studies	81
3.7 Anti Bacterial Activity of cystatin	82
3.8 Kinetics of inhibition	83
3.9 Spectral analysis	86
3.10 Glycation of purified BLC with reducing sugars	87
3.11a Unfolding studies and amyloid fibril formation	88
3.11b Amyloid fibril formation of BLC	90
3.12 Interaction of bilirubin with BLC	90
3.13 Effect of certain ligands having easy access to liver tissues	92
4.0 RESULTS	
CHAPTER-I	
4.1 PURIFICATION AND CHARACTERIZATION OF BUFFALO LIVER CYSTATIN	95-122
4.1.1 Purification of buffalo liver cystatin	95
4.1.2 Affinity chromatography	95
4.1.3 Homogeneity of the purified inhibitor	98
4.1.4 Reducing and non-reducing SDS-page	98
4.1.5 Properties of the purified liver cystatin	98

4.1.6	Immunological properties	101
4.1.7	Kinetic properties of buffalo liver cystatin	103
4.1.8	Antibacterial activity of BLC	117
4.1.9	Spectral analysis	117
DISCUSSION: CHAPTER-1		123-127
CHAPTER-2		
4.2	INTERACTION OF BUFFALO LIVER CYSTATIN WITH BILIRUBIN	128-150
4.2.1	Structural changes and binding of Bilirubin with BLC	128
4.2.2	UV-vis absorption studies of BR-BLC complex	129
4.2.3	Inhibitory activity of BLC in presence of (BR)	133
4.2.4	FT-IR measurements of BLC in the presence of bilirubin (BR).	133
4.2.5	Effect of pH on cystatin-BR complex	136
4.2.6	Effect of varying time of incubation on BR-cystatin complex	139
4.2.7	Effect of photo-illumination on BR-cystatin complex	144
DISCUSSION: CHAPTER-2		146-150
CHAPTER-3		
4.3	EFFECT OF REDUCING SUGARS ON LIVER CYSTATIN	151-174
4.3.1	Effect of sugars on the inhibitory activity of cystatin	151
4.3.2	Effect on the spectral properties of liver cystatin on incubation with sugars	152
4.3.2	Fluorescence spectroscopy studies	152
4.3.3	CD measurements of BLC in presence of reducing sugars	161
4.3.4	Advanced glycation end product (Age's) specific fluorescence	167
DISCUSSION: CHAPTER-3		170-184
CHAPTER-4		175-206
(A)	UNFOLDING STUDIES OF BUFFALO LIVER CYSTATIN (BLC) IN THE PRESENCE OF ACIDIC PH CONDITIONS	175-186
4.4.1	Effect of pH on the inhibitory activity of BLC	175
4.4.2	Fluorescence studies of BLC at different pH values	175

4.4.3	Extrinsic fluorescence studies of BLC at low pH conditions and TFE	177
4.2.4	Secondary structural analysis of BLC	181
(B)	FIBRIL FORMATION OF BUFFALO LIVER CYSTATIN (BLC)	187-199
4.4.5	Thioflavin T binding studies	187
4.4.6	Fourier Transform Infrared Spectroscopy (FTIR)	188
4.4.7	Atomic Force Microscopy (AFM)	193
	DISCUSSION: CHAPTER-4	200-206
	CHAPTER-5	207-230
	4.5A: PROTEIN DRUG INTERACTION	207-215
4.5.1	Intrinsic fluorescence spectra of rifampicin-cystatin complex	208
4.5.1	Determination of binding constant (K) and number of binding sites (n)	209
4.5.2	UV-visible absorption studies of rifampicin-BLC complex	213
4.5.3	Inhibitory activity of cystatin in the presence of rifampicin	213
	4.5B: INTERACTION OF BUFFALO LIVER CYSTATIN WITH STATIN (ATORVASTATIN)	216-222
4.5.4	Fluorescence spectra of statin-cystatin complex	216
4.5.1	Determination of binding constant (K) and number of binding sites (n)	216
4.5.5	UV-vis absorption spectra of Atrovastatin-cystatin complex	220
4.5.6	Inhibitory activity profile of statin-cystatin complex	220
	4.5C: INTERACTION OF PESTICIDE (MELATHION) WITH BUFFALO LIVER CYSTATIN	223-227
4.5.1	Intrinsic fluorescence spectra of melathion -cystatin complex	223
4.5.5	UV-vis absorption spectra of melathion-BLC complex	224
4.5.6	Inhibitory activity spectra of melathion-cystatin complex	224
	DISCUSSION: CHAPTER-5	228-230
	5.0 BIBLIOGRAPHY	231-265